Status:
WITHDRAWN
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
Lead Sponsor:
Pfizer
Conditions:
Aspergillosis
Invasive Pulmonary Aspergillosis
Eligibility:
All Genders
2-17 years
Phase:
PHASE3
Brief Summary
This study aims to compare the safety, tolerability, and efficacy of voriconazole and anidulafungin in combination versus voriconazole alone in pediatric subjects aged 2 to 17 years with invasive aspe...
Eligibility Criteria
Inclusion
- Diagnosis of proven, probable, or possible invasive aspergillosis.
- Hematologic malignancy or allogeneic hematopoetic stem cell transplant.
Exclusion
- Sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis.
- Chronic invasive aspergillosis.
- Receipt of antifungal treatment for more than 96 hours.
- Severe liver dysfunction.
Key Trial Info
Start Date :
May 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01188759
Start Date
May 1 2012
End Date
August 1 2014
Last Update
May 11 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.